Haemonetics Corp [NYSE: HAE] stock went on a downward path that fall over -26.58% on Thursday, amounting to a one-week price decrease of less than -24.86%.
Over the last 12 months, HAE stock dropped by -28.75%. The one-year Haemonetics Corp stock forecast points to a potential upside of 39.07. The average equity rating for HAE stock is currently 1.10, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.67 billion, with 48.22 million shares outstanding and 47.37 million shares in the current float. Compared to the average trading volume of 569.90K shares, HAE stock reached a trading volume of 5366051 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Haemonetics Corp [HAE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HAE shares is $91.30 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HAE stock is a recommendation set at 1.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Haemonetics Corp shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 09, 2025. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on June 26, 2025, representing the official price target for Haemonetics Corp stock. Previously, the target price had yet another drop from $95 to $68, while BofA Securities kept a Underperform rating on HAE stock.
The Price to Book ratio for the last quarter was 3.27, with the Price to Cash per share for the same quarter was set at 6.39. Price to Free Cash Flow for HAE in the course of the last twelve months was 18.76 with Quick ratio for the last quarter at 0.99.
HAE Stock Performance Analysis:
Haemonetics Corp [HAE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -24.86. With this latest performance, HAE shares dropped by -28.24% in over the last four-week period, additionally sinking by -21.91% over the last 6 months – not to mention a drop of -28.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HAE stock in for the last two-week period is set at 19.70, with the RSI for the last a single of trading hit 3.77, and the three-weeks RSI is set at 2.72 for Haemonetics Corp [HAE]. The present Moving Average for the last 50 days of trading for this stock 72.90, while it was recorded at 71.72 for the last single week of trading, and 71.72 for the last 200 days.
Insight into Haemonetics Corp Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Haemonetics Corp [HAE] shares currently have an operating margin of 15.79% and a Gross Margin at 52.32%. Haemonetics Corp’s Net Margin is presently recorded at 12.32%.
Haemonetics Corp (HAE) Capital Structure & Debt Analysis
According to recent financial data for Haemonetics Corp. ( HAE), the Return on Equity (ROE) stands at 18.83%, reflecting robust shareholder value creation. The Return on Assets (ROA) is 7.22%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Haemonetics Corp’s Return on Invested Capital (ROIC) is 9.35%, showcasing its effectiveness in deploying capital for earnings.
Haemonetics Corp (HAE) Efficiency & Liquidity Metrics
Based on Haemonetics Corp’s (HAE) latest financial statements, the Debt-to-Equity Ratio is 1.56%, indicating its reliance on debt financing relative to shareholder equity.
Haemonetics Corp (HAE) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Haemonetics Corp. (HAE) effectively leverages its workforce, generating an average of $55468.08 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.62% and a Quick Ratio of 0.99%, indicating strong ability to cover short-term liabilities.
HAE Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HAE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Haemonetics Corp go to 10.96%.
Haemonetics Corp [HAE] Institutonal Ownership Details
There are presently around $117.86%, or 119.24%% of HAE stock, in the hands of institutional investors. The top three institutional holders of HAE stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 6.92 million shares, which is approximately 13.5744%. BLACKROCK INC., holding 5.96 million shares of the stock with an approximate value of $$493.0 million in HAE stocks shares; and BLACKROCK INC., currently with $$425.29 million in HAE stock with ownership which is approximately 10.0911%.
